Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally

Stock Track

07/02

SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.

The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.

Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1123977572"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123977572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123977572?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123977572","market":"us","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally","media":"Stock Track","content":"<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-02 10:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1123977572","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123977572","pubTimestamp":1782958283,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|SBP集团盘中大涨7.26%，因战略AI投资、药物获批和板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}